Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. doi: 10.1093/rheumatology/kep107. Review.

2.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

3.

[Pulmonary arterial hypertension and systemic sclerosis].

Launay D, Humbert M, Hachulla E.

Presse Med. 2006 Dec;35(12 Pt 2):1929-37. Review. French.

PMID:
17159719
4.
5.

Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.

Ghosh SK, Corkill MM, Hart HH, Ng KP.

N Z Med J. 2014 Aug 15;127(1400):30-8.

PMID:
25145365
6.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.

Eur Respir J. 2007 Mar;29(3):469-75. Epub 2006 Nov 1.

7.

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE.

Arthritis Rheum. 2009 Feb;60(2):569-77. doi: 10.1002/art.24267.

8.

Current pharmacological treatment of pulmonary arterial hypertension.

Steiropoulos P, Trakada G, Bouros D.

Curr Clin Pharmacol. 2008 Jan;3(1):11-9. Review.

PMID:
18690874
10.

Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.

Beghetti M, Galiè N.

J Am Coll Cardiol. 2009 Mar 3;53(9):733-40. doi: 10.1016/j.jacc.2008.11.025. Review.

11.
12.

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

McLaughlin VV.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5.

PMID:
16919005
13.

Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.

Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.

Health Technol Assess. 2009 Oct;13(49):1-320. doi: 10.3310/hta13490. Review.

14.

Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.

Hachulla E, Denton CP.

Eur Respir Rev. 2010 Dec;19(118):314-20. doi: 10.1183/09059180.00007810. Review.

15.

[Treatment of pulmonary arterial hypertension associated to systemic sclerosis].

Hachulla E.

Rev Med Interne. 2004 Mar;25(3):195-200. Review. French.

PMID:
15049280
16.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
17.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
18.

Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.

Shimizu M, Hashida Y, Ueno K, Yokoyama T, Nakayama Y, Saito T, Ohta K, Takehara K, Yachie A.

Pediatr Cardiol. 2011 Oct;32(7):1040-2. doi: 10.1007/s00246-011-0056-z. Epub 2011 Jul 26.

PMID:
21789477
19.

The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.

Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A; Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators.

Ann Rheum Dis. 2012 Feb;71(2):249-52. doi: 10.1136/annrheumdis-2011-200265. Epub 2011 Oct 13.

PMID:
21998119
20.

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Shetty N, Derk CT.

Inflamm Allergy Drug Targets. 2011 Feb;10(1):19-26. Review.

PMID:
21184655
Items per page

Supplemental Content

Write to the Help Desk